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Abstract 
Purpose: To systemically explore the pharmacological mechanisms of traditional Chinese medicine, 
Yinlai Decoction (YD), used in the clinical management of pediatric diseases such as pneumonia and 
recurrent respiratory tract infections. 
Methods: An ingredient-target-disease database of YD was constructed using Traditional Chinese 
Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). First, the molecular 
targets related to lung and stomach diseases were searched and screened to avoid duplication. 
Second, the associations between these molecular targets were evaluated via Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING) and Gene Ontology (GO) and Pathway enrichment 
analysis in STRING. 
Results: A total of 627 chemical ingredients and 654 protein targets in YD were obtained. After further 
screening, 38 molecular targets linked to respiratory diseases, inflammatory responses and various 
infections were identified. Finally, 576 GO terms and 75 KEGG pathway terms were obtained by 
analyzing gene functional annotation clusters and abundance value of these targets. Most of these 
terms were closely related to the inflammatory response. 
Conclusion: Based on these in silico findings, the use of YD for treating respiratory diseases, 
inflammation and various infections, most probably via the suppression of inflammation, has been 
established. The approach adopted in this study can serve as a model methodology to develop an 
innovative TCM candidate drug at a network pharmacology level. 
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Yinlai Decoction (YD) is an empirical formula 
used to treat lung and stomach diseases, 
especially pneumonia and recurrent respiratory 
tract infections in children. This traditional 
formula is composed of Lonicerae japonicae 
Flos, Raphani semen, Forsythiae fructus, 
Scutellariae radix, Houttuyniae herba, Peucedani 
radix and Trichosanthes kirilowii Maxim [1]. 
Biological mechanisms of YD have been related 
to the regulation of expression of inflammatory 
factors, such as tumor necrosis factor-α (TNF-α) 
and interleukin-6 (IL-6) [2-4]. Moreover, the 
existing experimental data is either fragmented 
or confined to a single index or one pathway, 
thus it cannot reflect the overall multi-target 
regulation of this traditional Chinese medicine’s 
characteristics. 
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On account of this deficiency in knowledge, we 
have introduced system theory as an attempt to 
explore the possible mechanism of YD. Network 
pharmacology is an emerging discipline, which is 
useful to study the progression of disease, the 
interaction of drug with the body and the 
discovery of new drugs from the perspective of 
biological networks [5]. The basic idea of network 
pharmacology is to intervene the pathological 
network of disease, rather than just individual 
genes associated with disease, to achieve a 
comprehensive prevention and treatment effects. 
 
By analyzing the existing databases, we sorted 
out all chemical ingredients present in YD. 
Targets of all these chemical molecules were 
identified, and then the related pathways or 
diseases for each target were annotated. 
Through correlation and pathway analysis of 
targets related to the lung and stomach diseases 
treatable with YD, we predicted network-based 






Traditional Chinese Medicine Systems 
Pharmacology Database and Analysis Platform 
(TCMSP, http://lsp.nwsuaf.edu.cn/tcmsp.php) is 
a unique platform of system pharmacology for 
Chinese herbal medicines that that renders a 
relationship between drugs, molecular targets 
and diseases states. This database is not only 
accompanying with various pharmacological 
networks, but also exhibits pharmacokinetic 
features of natural drugs such as solubility, 
permeability and bioavailability. This 
advancement has initiated a new thematic 
search to find candidate drugs in different types 
of traditional Chinese herbs [6]. All chemicals of 
each herb and all targets of each chemical were 
retrieved through TCMSP and the available 
literature. Specific retrieval steps were: (i) 
retrieval of YD ingredients; (ii) target search of 
each chemical, then (iii) building of chemical-




A target-disease database was developed after 
retrieval of the related diseases of each target 
through TCMSP. Afterwards, the corresponding 
molecular targets of these chemical ingredients 
were identified for further analysis. 
 
Network construction and analysis 
 
For systematic investigation of mechanism of 
YD, the interaction between these molecular 
targets were analyzed through Search Tool for 
the Retrieval of Interacting Genes / Proteins 
(STRING, http://string-db.org/). STRING data-
base is an excellent source of hundreds of 
known interactions between proteins as well as is 
capable of predicting interactions. This database 
retrieves the knowledge of both physical (direct) 
and functional (indirect) interactions from four 
different sources of information such as genomic 
literature, high-throughput screening, co-
expression and the published information. 
STRING combines the interaction data from 
these sources for hundreds of organisms, and 
transfers information between these organisms 
where applicable. This database presently 
covers 9,643,763 proteins from 2,031 organisms 
[7]. 
 
The relationship between herbs and the 
screened targets was analyzed by constructing 
target-herb network to investigate the 
mechanism of YD and its significance of 
pharmacodynamic composition. The network 
was generated by Cytoscape 3.4.0 [8]. 
 
Gene ontology and pathway enrichment 
analysis 
 
In order to identify and analyze the specific 
biological properties of the potential targets, 
Gene Ontology (GO) biological processes were 
introduced to dissect target genes in a 
hierarchically structured way based on the 
characteristic biological terms. Pathway 
enrichment analysis was introduced to probe the 
mechanisms of YD for related diseases. Both GO 
terms and KEGG pathway terms were obtained 
from STRING. Then, more information of these 
pathways were acquired from Kyoto 







A total of 236 molecular compounds in Lonicerae 
japonicae Flos and 388 potential targets, 52 
molecular compounds in Raphani semen and 
103 targets, 80 molecular compounds in 
Forsythiae fructus and 323 targets, 58 molecular 
compounds in Scutellariae radix and 197 targets, 
208 molecular compounds in Houttuyniae herba 
and 50 targets, 101 molecular compounds in 
Peucedani radix and 369 targets, and 150 
molecular compounds and 362 targets in 
Trichosanthes kirilowii Maxim were obtained. 
Chemical compounds and their targets were 
merged to remove overlapping. As a result, 627 
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molecular compounds and 654 potential targets 
in YD were found. 
 
Targets and the related diseases 
 
According to early experimental results and 
clinical applications, YD could be used to treat 
inflammation, respiratory diseases and bacterial 
and viral infections. Out of 654 targets of YD, 38 
targets related to these diseases screened out 
and mapped to the database UniProt 
(http://www.uniprot.org/) for normalization. 
 
Out of these 38, 33 protein targets were found to 
exist in Homo sapiens (Table 1). Beta-
lactamases (β-lactamases) are enzymes (EC 
3.5.2.6) produced by bacteria that provide 
resistance to β-lactam antibiotics such as the 
penicillins, cephamycins, and carbapenems. 
 




Target  Gene 
names 
Diseases 
P35354 Prostaglandin G/H synthase 2 PTGS2 Inflammation, Inflammatory diseases 
P23219 Prostaglandin G/H synthase 1 PTGS1 Chronic inflammatory diseases 
P05231 Interleukin-6 IL6 Inflammatory Disorders, Unspecified 
P29474 Nitric-oxide synthase, endothelial NOS3 Inflammation; Sepsis 
P07550 Beta-2 adrenergic receptor ADRB2 Inflammation; Chronic obstructive pulmonary 
disease, unspecified 
P01375 Tumor necrosis factor TNF Chronic inflammatory diseases; Periodic fever 
syndrome 
Q02880 DNA topoisomerase II TOP2B Bacterial Infections; Herpes virus infection 
P08172 Muscarinic acetylcholine receptor 
M2 




Peroxisome proliferator activated 
receptor gamma 
PPARG Chronic inflammatory diseases, Inflammation 
P09960 Leukotriene A-4 hydrolase LTA4H Inflammation 
P09917 Arachidonate 5-lipoxygenase ALOX5 Inflammatory bowel disease; Inflammatory lung 
disease 
Q03181 Peroxisome proliferator activated 
receptor delta 
PPARD Inflammation 
P13500 C-C motif chemokine 2 CCL2 Chronic obstructive pulmonary disease, 
unspecified; Inflammatory diseases associated 
with hypoxia 
P01584 Interleukin-1 beta IL1B Acne; Pediatric 
P15692 Vascular endothelial growth factor A VEGFA Viral infection; Herpes virus infection 
P35372 Mu-type opioid receptor OPRM1 Cough 
P11926 Ornithine decarboxylase ODC1 Inflammation 
Q13085 Acetyl-CoA carboxylase 1 ACACA Bacterial Infections 
Q16539 Mitogen-activated protein kinase 14 MAPK14 Endotoxemia; Inflammation; 
Q16881 Thioredoxin reductase, cytoplasmic TXNRD1 Bacterial Infections; Oxidative and free radical 
damage; Pneumocystis infections; 
P45983 Mitogen-activated protein kinase 8 MAPK8 Inflammatory Disorders, Unspecified 
P16581 E-selectin SELE Chronic Obstructive Pulmonary Disease (COPD); 
P13726 Tissue factor F3 Sepsis 
P04054 Phospholipase A2 PLA2G1B Inflammation 
P07858 Cathepsin B CTSB Acute otitis media 
P22894 Neutrophil collagenase MMP8 Inflammatory diseases 
O14920 Inhibitor of nuclear factor kappa B 
kinase beta subunit 
IKBKB Inflammation; Inflammatory lung disease 
P14416 D(2) dopamine receptor DRD2 Nausea and vomiting; Respiratory diseases 
P50406 5-hydroxytryptamine 6 receptor HTR6 Nausea and vomiting 
P41143 Delta-type opioid receptor OPRD1 Cough 
P45984 Mitogen-activated protein kinase 9 MAPK9 Inflammation 
P24941 Cell division protein kinase 2 CDK2 Viral infection, unspecified 
P08311 Cathepsin G CTSG Chronic Obstructive Pulmonary Disease (COPD) 
 Beta-lactamase  Bacterial Infections 
 DNA polymerase (HSV)  Herpes virus infection; Viral infection, unspecified 
 P-hydroxybenzoate hydroxylase  Inflammation 
 Rhinovirus coat protein  Acute nasopharyngitis (common cold) 
 Streptavidin  Bacterial Infections 
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DNA polymerase (HSV), encoded by herpes 
simplex virus (HSV), can selectively replicate 
viral DNA through a variety of mechanisms. 
Rhinovirus coat protein is thought to cause 
Rhinoviral infection. It indicates that YD may cure 
bacterial infections through decreasing drug 
resistance by acting as natural inhibitors of β-
lactamases, and play a role of antivirus by 
inhibiting DNA polymerase and rhinovirus coat 
protein. 
 
Target-target interaction (T-T) networks 
 
The protein interaction network of 33 target 
genes was constructed using STRING (Figure 1). 
Genes were denoted as nodes and interactions 
between gene pairs were presented as edges 
(lines) in the image. A total of 33 nodes and 127 
edges composed the acquired interaction 
network. The degree of each node is shown in 
Table 2. Average node degree and the clustering 
coefficient were 7.7 and 0.617, respectively for 
this network having no PPI enrichment value. In 
the network, the degree of node (the number of 
connections or edges the node has with other 
nodes) is one of the most basic quantitative 
properties and the nodes with high degree are 
considered as hubs. Of the 33 proteins, 15 
proteins possess node degree larger than 8 
under an average value of 7.7, therefore, these 
candidate proteins participating in more 
interactions than other proteins are the hubs in 
this T-T Network. In the network, TNF (Tumor 
necrosis factor) was the node with the highest 
degree (DD = 19), followed by PTGS2 
(Prostaglandin G/H synthase 2, DD = 18), IL6 
(Interleukin-6, DD = 17), IL1B (Interleukin-1 beta, 
DD = 14), MAPK14 (Mitogen-activated protein 
kinase 14, DD = 14), PPARG (Peroxisome 
proliferator activated receptor gamma, DD = 13), 
VEGFA (Vascular endothelial growth factor A, 
DD = 13), CCL2 (C-C motif chemokine 2, DD = 
12), NOS3 (Nitric-oxide synthase, endothelial, 
DD = 12) and MAPK8 (Mitogen-activated protein 
kinase 8, DD = 12). Most of these proteins show 
close relationships with inflammation. In addition, 
OPRD1 (Delta-type opioid receptor, DD = 4), 
DRD2 (D(2) dopamine receptor, DD = 3), 
CHRM2 (Muscarinic acetylcholine receptor M2, 
DD = 5) and OPRM1 (Mu-type opioid receptor, 
DD = 5) showed a closely interaction with each 




Figure 1: Protein interaction networks based on search tool for the retrieval of interacting 
genes/proteins database. Genes are denoted as nodes and interactions between gene pairs are 
presented as edges (lines) in the image. A total of 33 nodes and 127 edges constitute this interaction 
network 
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For further studying the relationship between 
targets and herbs, we constructed herb-target 
network using Cytoscape (Figure2). The 
information of the related targets-herbs are 
shown in Table 3. In the network, PTGS2, 
PTGS1, IL6, NOS3, ADRB2, TNF, TOP2 and 
CHRM2 were the nodes with the highest degree 
(DD = 7), followed by PPARG, LTA4H, ALOX5 
and PPARD (DD = 6), CDK2, CCL2, IL1B, 
VEGFA, OPRM1, ODC1, ACACA (DD = 5), 
MAPK14, TXNRD1, MAPK8, SELE and F3 (DD 
= 4). 
 
Table 2: The degree of each node present in network 
 
Node Degree Node    Degree Node Degree 
TNF 19 ALOX5 8 ACACA 4 
PTGS2 18 PPARD 8 ADRB2 4 
IL6 17 PTGS1 8 OPRD1 4 
IL1B 14 MMP8 8 CTSG 4 
MAPK14 14 F3 7 OPRM1 3 
PPARG 13 MAPK9 7 PLA2G1B 3 
VEGFA 13 TOP2B 5 DRD2 3 
CCL2 12 CHRM2 5 LTA4H 2 
NOS3 12 CTSB 5 ODC1 2 
MAPK8 12 IKBKB 5 TXNRD1 2 
SELE 9 CDK2 5 HTR6 1 
 
 
Figure 2: Herb-target networks. The red circles represent herbs in YD, while the white circles 
represent target proteins, and each edge represents the interaction between them. 
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Table 3: Target-herb relationship 
 
Target Degree Herb Target Degree Herb 
PTGS2 7 GL;HQ;JYH;LFZ;LQ;QH;YXC MAPK14 4 GL;HQ;JYH;LQ 
PTGS1 7 GL;HQ;JYH;LFZ;LQ;QH;YXC TXNRD1 4 GL;JYH;LQ;QH 
IL6 7 GL;HQ;JYH;LFZ;LQ;QH;YXC MAPK8 4 JYH;LQ;QH;YXC 
NOS3 7 GL;HQ;JYH;LFZ;LQ;QH;YXC SELE 4 JYH;LQ;QH;YXC 
ADRB2 7 GL;HQ;JYH;LFZ;LQ;QH;YXC F3 4 JYH;LQ;QH;YXC 
TNF 7 GL;HQ;JYH;LFZ;LQ;QH;YXC PLA2G1B 3 GL;JYH;QH 
TOP2 7 GL;HQ;JYH;LFZ;LQ;QH;YXC CTSB 3 JYH;LQ;QH 
CHRM2 7 GL;HQ;JYH;LFZ;LQ;QH;YXC MMP8 1 GL 
PPARG 6 GL;HQ;JYH;LQ;QH;YXC IKBKB 1 GL 
LTA4H 6 GL;HQ;JYH;LFZ;LQ;QH DRD2 1 LQ 
ALOX5 6 GL;HQ;JYH;LQ;QH;YXC HTR6 1 QH 
PPARD 6 GL;HQ;JYH;LQ;QH;YXC OPRD1 1 QH 
CDK2 5 GL;HQ;JYH;LQ;QH MAPK9 1 QH 
CCL2 5 HQ;JYH;LQ;QH;YXC CTSG 1 QH 
IL1B 5 HQ;JYH;LQ;QH;YXC Beta-lactamase 6 GL;HQ;JYH;LFZ;LQ;QH 
VEGFA 5 HQ;JYH;LQ;QH;YXC Rhinovirus coat 
protein 
2 GL;JYH 
OPRM1 5 HQ;JYH;LQ;QH;YXC DNA polymerase 
(HSV) 
2 GL;QH 
ODC1 5 HQ;JYH;LQ;QH;YXC P-hydroxybenzoate 
hydroxylase 
1 JYH 
ACACA 5 HQ;JYH;LQ;QH;YXC Streptavidin 1 QH 
Note: GL = Trichosanthes kirilowii Maxim; HQ = Scutellariae radix; LQ = Forsythiae fructus; JYH = 
Lonicerae japonicae Flos; LFZ = Raphani semen; QH = Peucedani radix; YXC = Houttuyniae herba 
 
Go and pathway analysis data 
 
To analyze biological functions of these potential 
targets, GO and Pathway enrichment analysis 
was conducted. We obtained 576 GO terms 
(Biological Process) and 75 KEGG pathways 
(False Discovery Rate, FDR < 0.05) (Table 4). It 
is interesting to note that these targets are 
involved in a variety of biological processes 
including response to oxygen-containing 
compound and regulation of cell proliferation, 
response to bacterium. These biological 
processes are largely related to transcriptional 
regulation, immune response, and apoptosis. It 
indicates that these biological processes have a 
close relationship with inflammation. Of 75 
KEGG pathway terms, TNF signaling pathway, 
NOD-like receptor signaling pathway, influenza A 
and toll-like receptor signaling pathway have the 
lowest FDR. Four pathways are associated with 
virus infection, immune tolerance, immune 
response and inflammatory response, which play 





YD is effective in amiolerating lung condition, 
relieving exterior syndrome, relaxing the bowels 
and removing food retention, and has been used 
for treating pediatric diseases, especially 
pneumonia and recurrent respiratory tract 
infection [9-14]. However, the precise 
mechanisms of YD action in these diseases are 
still unclear. Thus, system pharmacology method 
combining the screening drug targeting, network 
construction, and pathway analysis was carried 
out in this work to uncover the active ingredients, 
targets, and pathways of YD and systematically 
deciphered its therapeutic mechanism of actions 
[15]. Our results showed that 627 ingredients and 
654 potential targets were obtained from YD, and 
37 targets were screened out. GO analysis of 
these targets and integrated herb-target network 
analysis demonstrated the synergistic e ect of 
YD ingredients in treating the related diseases 
mainly through boosting of immune system, 
inhibiting inflammatory response, and 
inhibiting/killing pathogens as well as decreasing 
drug resistance [15]. Meanwhile, the pathway 
analysis in our work shows that YD might 
simultaneously regulate multitargets/pathways 
coupled with a range of therapeutic modules, for 
example, the suppression of inflammation and 
virus/bacterial infections and decreasing drug 
resistance [12]. Previous studies have shown 
that YD could boost immune system, inhibit 
inflammatory response and ease the damage 
caused by inflammation through reduction of 
expression of IL-6 and TNF-α and increasing the 
expression of IL-2, IL-10, IFN-γ, SIgA and IgM 
[3]. In this study, GO enrichment analysis, 
network analysis and pathway analysis exhibited 
that YD significantly enriches target genes 
involved in reducing the inflammation response, 
enhancing immunity and combating 
viral/bacterial growth. 
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Table 4: Part of the GO terms and pathway terms of the potential targets  
 









GO:1901700 Response to oxygen-containing compound 19 2.20E-11 
GO:0009612 Response to mechanical stimulus 11 2.47E-11 
GO.0033993 Response to lipid 16 2.47E-11 
GO.0010033 Response to organic substance 22 1.25E-10 
GO.0010243 Response to organonitrogen compound 15 2.54E-10 
GO.0042127 Regulation of cell proliferation 18 3.84E-10 
GO.0044707 Single-multicellular organism process 28 3.84E-10 
GO.0051707 Response to other organism 14 4.10E-10 
GO.1901698 Response to nitrogen compound 15 4.99E-10 
GO.0071310 Cellular response to organic substance 19 6.43E-10 
GO.0009628 Response to abiotic stimulus 16 6.92E-10 
GO.0051240 Positive regulation of multicellular organismal process 17 6.92E-10 
GO.0097305 Response to alcohol 11 7.84E-10 
GO.0008284 Positive regulation of cell proliferation 14 2.12E-09 
GO.0051049 Regulation of transport 18 2.18E-09 
GO.0032496 Response to lipopolysaccharide 10 5.19E-09 
GO.0051050 Positive regulation of transport 14 5.65E-09 
GO.0009605 Response to external stimulus 18 6.79E-09 
GO.0070482 Response to oxygen levels 10 8.56E-09 
GO.0009719 Response to endogenous stimulus 16 1.27E-08 
GO.0032879 Regulation of localization 19 1.27E-08 
GO.0023056 Positive regulation of signaling 16 1.79E-08 









4668 TNF signaling pathway 9 1.90E-11 
4621 NOD-like receptor signaling pathway 7 4.53E-10 
5164 Influenza A 7 5.24E-07 
4620 Toll-like receptor signaling pathway 6 5.93E-07 
590 Arachidonic acid metabolism 5 1.59E-06 
5133 Pertussis 5 2.65E-06 
4080 Neuroactive ligand-receptor interaction 7 5.69E-06 
5168 Herpes simplex infection 6 7.02E-06 
4370 VEGF signaling pathway 4 4.30E-05 




The results of this study describe important 
molecular targets and signaling pathways of YD.  
It is concluded that the mechanisms of YD for 
related diseases mainly include restoring the 
immune system and enhancing immune 
response, alleviating the symptoms of 
inflammation disorders, and combating the 
spreading virus/bacterial. This study not only 
made a contribution to a better understanding of 
the mechanisms of YD, but also proposed a 
strategy to develop novel TCM candidates at a 
network pharmacology level. However, this study 
contains only those ingredients and targets of YD 
that have been published in literature. Thus, 
further studies such as docking and MD 
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